344 related articles for article (PubMed ID: 23172750)
1. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.
Smolen JS; Schoels MM; Nishimoto N; Breedveld FC; Burmester GR; Dougados M; Emery P; Ferraccioli G; Gabay C; Gibofsky A; Gomez-Reino JJ; Jones G; Kvien TK; Murakami M; Betteridge N; Bingham CO; Bykerk V; Choy EH; Combe B; Cutolo M; Graninger W; Lanas A; Martin-Mola E; Montecucco C; Ostergaard M; Pavelka K; Rubbert-Roth A; Sattar N; Scholte-Voshaar M; Tanaka Y; Trauner M; Valentini G; Winthrop KL; de Wit M; van der Heijde D
Ann Rheum Dis; 2013 Apr; 72(4):482-92. PubMed ID: 23172750
[TBL] [Abstract][Full Text] [Related]
2. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
Aletaha D; Kerschbaumer A; Kastrati K; Dejaco C; Dougados M; McInnes IB; Sattar N; Stamm TA; Takeuchi T; Trauner M; van der Heijde D; Voshaar M; Winthrop KL; Ravelli A; Betteridge N; Burmester GR; Bijlsma JW; Bykerk V; Caporali R; Choy EH; Codreanu C; Combe B; Crow MK; de Wit M; Emery P; Fleischmann RM; Gabay C; Hetland ML; Hyrich KL; Iagnocco A; Isaacs JD; Kremer JM; Mariette X; Merkel PA; Mysler EF; Nash P; Nurmohamed MT; Pavelka K; Poor G; Rubbert-Roth A; Schulze-Koops H; Strangfeld A; Tanaka Y; Smolen JS
Ann Rheum Dis; 2023 Jun; 82(6):773-787. PubMed ID: 35953263
[TBL] [Abstract][Full Text] [Related]
3. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
McLaughlin M; Östör A
Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
Song SN; Yoshizaki K
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab in the treatment of rheumatoid arthritis and beyond.
Shetty A; Hanson R; Korsten P; Shawagfeh M; Arami S; Volkov S; Vila O; Swedler W; Shunaigat AN; Smadi S; Sawaqed R; Perkins D; Shahrara S; Sweiss NJ
Drug Des Devel Ther; 2014; 8():349-64. PubMed ID: 24729685
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
Mitchell E; Jones G
Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
[TBL] [Abstract][Full Text] [Related]
7. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.
Schoels MM; van der Heijde D; Breedveld FC; Burmester GR; Dougados M; Emery P; Ferraccioli G; Gabay C; Gibofsky A; Gomez-Reino JJ; Jones G; Kvien TK; Murakami M; Nishimoto N; Smolen JS
Ann Rheum Dis; 2013 Apr; 72(4):583-9. PubMed ID: 23144446
[TBL] [Abstract][Full Text] [Related]
8. [Tocilizumab in rheumatoid arthritis].
Rueda Gotor J; Blanco Alonso R
Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769
[TBL] [Abstract][Full Text] [Related]
9. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.
Woodrick RS; Ruderman EM
Bull NYU Hosp Jt Dis; 2012; 70(3):195-9. PubMed ID: 23259628
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis.
Ogata A; Kato Y; Higa S; Maeda K
Expert Opin Drug Deliv; 2019 Jun; 16(6):639-648. PubMed ID: 31088167
[TBL] [Abstract][Full Text] [Related]
11. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab (Actemra).
Sheppard M; Laskou F; Stapleton PP; Hadavi S; Dasgupta B
Hum Vaccin Immunother; 2017 Sep; 13(9):1972-1988. PubMed ID: 28841363
[TBL] [Abstract][Full Text] [Related]
13. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
Avci AB; Feist E; Burmester GR
BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
[TBL] [Abstract][Full Text] [Related]
14. A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
Nakagawa J; Koyama Y; Kawakami A; Ueki Y; Tsukamoto H; Horiuchi T; Nagano S; Uchino A; Ota T; Akahoshi M; Akashi K
Arthritis Res Ther; 2017 Aug; 19(1):185. PubMed ID: 28800780
[TBL] [Abstract][Full Text] [Related]
15. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.
June RR; Olsen NJ
Expert Opin Biol Ther; 2016 Oct; 16(10):1303-9. PubMed ID: 27464017
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.
Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2019; 13():57-70. PubMed ID: 30587928
[TBL] [Abstract][Full Text] [Related]
17. Targeting interleukin-6 in rheumatoid arthritis.
Md Yusof MY; Emery P
Drugs; 2013 Mar; 73(4):341-56. PubMed ID: 23456676
[TBL] [Abstract][Full Text] [Related]
18. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis.
Kondo N; Fujisawa J; Endo N
Tohoku J Exp Med; 2020 May; 251(1):9-18. PubMed ID: 32404541
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of IL-6 blockade tocilizumab and TNF inhibitors on angiogenesis in synovial tissues from patients with rheumatoid arthritis.
Hirohata S; Abe A; Murasawa A; Kanamono T; Tomita T; Yoshikawa H
Mod Rheumatol; 2017 Sep; 27(5):766-772. PubMed ID: 27846751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
